Daniel Hetu
Managing Director @ Lumira Ventures
Montréal, Canada
Daniel Hetu is a Series A investor at Lumira Ventures in Montréal focused on Biotechnology and Health Care. With over 20 years of investment banking, corporate development, and licensing and investment experience, Daniel has been involved with life sciences companies at all stages of development in North America and overseas. With demonstrated success managing complex initiatives, projects and transactions, Daniel is recognized for his strategic thinkingand problem-solving skills.Daniel’s investment activities are focused on building companies in the therapeutics and medical device sectors that develop products and technologies with a direct and significant impact on patient care. He manages Lumira Ventures’ Montreal office.An experienced senior executive with leading expertise in financing and corporate business development, Daniel located in Montréal spent 10 years at Shire Pharmaceuticals and at Biochem Pharma prior to its acquisition by Shire. As vice president, business development (North America) and vice president, corporate development, respectively, he led several financing, licensing and M&A transactions in the therapeutics, vaccine and diagnostics sectors. At Biochem, as well as serving on the company’s portfolio committee and the steering committee of strategic research collaborations, Daniel served on the boards of investee companies. Prior to joining Biochem Pharma, Daniel was an investment banker at a major Canadian Investment Bank where he was involved in M&A and financing transactions across various industrial sectors.
- Total investments:
- 11
- Last investment:
- Lead investor:
- 18%
Last updated:
For AI agents: llms.txt
Industries Daniel Hetu invests in
Stages Daniel Hetu invests in
Countries Daniel Hetu invests in
Investment Focus
Industry
- Biotechnology 6 (55%)
- Health Care 2 (18%)
- Therapeutics 2 (18%)
- Medical 1 (9%)
- Medical Device 1 (9%)
Stage
- Series A 3 (27%)
- Series B 2 (18%)
- Seed 1 (9%)
- Funding Round 1 (9%)
- Post-IPO Equity 1 (9%)
Country
- Canada 5 (45%)
- United States 2 (18%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Congruence Therapeutics
|
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $39.5M / Venture - Series Unknown / Mar 19, 2026 | |
Thryv Therapeutics
|
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | Sep 17, 2025 | |
|
Congruence Therapeutics
|
Congruence Therapeutics operates as a biotechnology company working at the interface of computational and experimental drug discovery to design novel small molecules for diseases of protein misfolding. | $32M / Venture - Series Unknown / Sep 04, 2025 | |
Puzzle Medical Devices
|
Puzzle Medical is developing the ModulHeart, a modular percutaneous heart pump designed to reduce cardiac afterload and improve renal perfusion in patients with advanced heart failure who are not candidates for heart transplant or surgical mechanical circulatory support. The device’s modular design allows for hemodynamic support through multiplepumps anchored in parallel in the descending aorta. The design is expected to increase accessibility by enabling safe percutaneous implantation to support both renal and cardiac function, with low risk of bleeding, stroke, and pump thrombosis, while providing sustained symptom relief, reduced re-hospitalizations and improved overall quality of life. To date, Puzzle Medical has successfully:○ completed its first-in-human study with all patients experiencing improvements in cardiac and kidney function (2022); ○ completed a Seed financing round (2021); ○ built a strong Key Opinion Leaders committee (2021); ○ received U.S. Food and Drug Administration (FDA) Breakthrough Device Designation (2021). | $30.2M / Series A / Apr 08, 2025 | |
XyloCor Therapeutics
|
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively. | $67.5M / Series B / Jan 07, 2025 | |
KisoJi Biotechnology
|
KisoJi Biotechnology Inc. is an early stage biotechnology company engaged in the development of antibodies for the treatment of various cancers. | $40.6M / Series B / Dec 02, 2024 | |
|
Specific Biologics
|
Specific Biologics' mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body. | Seed / Oct 10, 2023 | |
|
Specific Biologics
|
Specific Biologics' mission is to develop novel gene editing technologies to treat diseases at the genetic level in cells inside the body. | Seed / Dec 16, 2021 | |
|
Thryv Therapeutics
|
Thryv Therapeutics is a genetic disorder that causes a prolongation between the beginning of the QRS complex and the end of the T waveQ and T waves on the EKG, indicating a prolongation of ventricular repolarization and the action potential duration. The lengthening of this complex is associated with unexpected and life-threatening ventriculararrhythmias. Click below to learn more about our programs. | $19M / Series A / Aug 10, 2021 | |
|
XyloCor Therapeutics
|
XyloCor Therapeutics is a bio-pharmaceutical company intended to develop gene therapy for people with advanced coronary artery disease. The company's service focuses on developing gene therapy to stimulate the formation of new coronary blood vessels and serve areas of the heart that are not receiving adequate blood supply, enabling patientswith refractory angina who exhausted pharmacologic options to cure their cardiovascular diseases painlessly and cost effectively. | $22.6M / Series A / Mar 22, 2021 | |
| See all 11 investments → | |||
Co-Investors
About Lumira Ventures
With a 30-year reputation as a leading North American healthcare and life sciences venture capital firm, with offices in Toronto, Montreal, Vancouver and Boston, Lumira Ventures collaborates with and invests in entrepreneurial management teams to build best-in-class, innovation-centric biotherapeutic and medical device companies that are meetingsignificant unmet needs and creating transformation impact in communities worldwide.Since 1989, Lumira Ventures has invested in over 100 healthcare companies and currently has a portfolio of 30+ active investee companies located in Canada and the United States.
Lumira Ventures Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Baye Galligan, M.A., HBA
Associate
|
|||
Benjamin Rovinski
Managing Director
|
|||
Brian J. Underdown, Ph.D.
Venture Partner
|
|||
|
Daniel Hetu
Managing Director
|
|||
Lu Han
Director, Business Development Asia Pacific
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Daniel Hetu invest in?
Daniel Hetu invests primarily in Biotechnology, Health Care and Therapeutics startups, most often at Series A and Series B stage. Most of the 11 investments tracked by Shizune back companies in Canada. The Investment Focus section breaks down every industry, stage and country in the portfolio.
When did Daniel Hetu last invest?
The most recent investment recorded for Daniel Hetu closed in Mar 2026. Shizune tracks 11 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
